Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
McKesson
Merck
Covington
Harvard Business School

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 10,189,797

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,189,797
Title:Chemical modulators of immune checkpoints and therapeutic use
Abstract: Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
Inventor(s): Chen; Wei (Chapel Hill, NC), Lyerly; Herbert Kim (Chapel Hill, NC), Ren; Xiu-rong (Durham, NC), Wang; Jiangbo (Durham, NC), Guo; Hongtao (Durham, NC), Hobeika; Amy (Durham, NC), Mook; Robert A. (Chapel Hill, NC)
Assignee: Duke University (Durham, NC)
Application Number:15/395,464
Patent Claims:see list of patent claims

Details for Patent 10,189,797

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Duke University (Durham, NC) 2035-12-30 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Duke University (Durham, NC) 2035-12-30 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Try a Free Trial Duke University (Durham, NC) 2035-12-30 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Try a Free Trial Duke University (Durham, NC) 2035-12-30 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Try a Free Trial Duke University (Durham, NC) 2035-12-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
McKinsey
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.